Mon, Dec 22, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing Weekly

Review of hedge fund launches, closures, trends, regulatory and legal events - week 29

Saturday, July 23, 2011

Last week saw only a few launches including one from Daniel Goldberg who announced plans to step down as head of Morgan Stanley's Brazilian unit to start a hedge fund specializing in high-risk credit products, and a launch from former Deephaven Capital manager Edouard Salet.

Highland Capital Management LP said it will take three years to complete the fund’s liquidation. A study by Dow Jones and Credit Suisse show that hedge funds are on pace to double 2010 investor inflows in 2011. However, assets in Swiss funds fell 2% in June on concerns over Eurozone debt problems.

The of Imperia Investment Group expanded to $65m because of fresh inflows, Jeffrey Gundlach’s hedge fund’s assets have risen 28% on mortgage-backed bonds since its launch in September 2010, and Gottex Fund Management assets are now at $8.9bn. Henderson Global Investors lost GBP 438 million of the assets when Gartmore Investment Management acquired it in the first half of the year. And, Blackstone Group reported its 2Q 2011 financial results and is expecting profit to increase to $703 million on $1.3 billion in revenues, up 243% or $498 million from the $205 million profit at the same time last year.

The performances of large hedge fund startups consistently show underperformance but typically easily raise money. Sluggish markets have stalled CTAs growth.

Individual fund performance for June continues to come in. The Toro 1A fund was up +0.98% in June (+27.82% YTD); The Midway Market Neutral Fund was up +1.75% in June (+22.17% YTD) to mark its 29th-month of consecutive wins.

The......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for